Verano Holdings (VRNO) Cash from Financing Activities (2021 - 2026)
Verano Holdings (VRNO) reported Cash from Financing Activities of -$12.4 million for Q1 2026, down 1994.42% year-over-year from $653393.9 in Q1 2025, and down 230.61% quarter-over-quarter from -$3.7 million in Q4 2025.
Verano Holdings (VRNO) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Cash from Financing Activities data on file, last reported at -$12.4 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$12.4 million, down 1994.42% year-over-year; the trailing twelve-month figure through Mar 2026 was -$37.1 million (up 42.2% YoY), and the FY2025 annual result was -$25.3 million, up 61.59% from the prior year.
- Cash from Financing Activities slipped to -$12.4 million in Q1 2026 per VRNO's latest filing, from -$3.7 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $92.8 million in Q1 2022 and troughed at -$53.2 million in Q2 2024.
- A 5-year average of $586705.9 and a median of -$2.3 million in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities surged 975.57% in 2023, then slumped 1994.42% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at $2.1 million in 2022, then surged by 975.57% to $22.3 million in 2023, then plunged by 137.15% to -$8.3 million in 2024, then surged by 54.84% to -$3.7 million in 2025, then plunged by 230.61% to -$12.4 million in 2026.
- Business Quant data shows VRNO's Cash from Financing Activities at -$12.4 million in Q1 2026, -$3.7 million in Q4 2025, and -$4.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | Verano Holdings | - | - | 98.98 Mn | -12.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.38 Mn |
| Mar 31, 2026 | -12.38 Mn |
| Dec 31, 2025 | -3.74 Mn |
| Dec 31, 2025 | -3.74 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Sep 30, 2025 | -4.85 Mn |
| Jun 30, 2025 | -16.14 Mn |
| Jun 30, 2025 | -16.14 Mn |
| Mar 31, 2025 | -591,000.00 |
| Mar 31, 2025 | -591,000.00 |
| Dec 31, 2024 | -8.29 Mn |
| Dec 31, 2024 | -8.29 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Sep 30, 2024 | -2.17 Mn |
| Jun 30, 2024 | -53.15 Mn |
| Jun 30, 2024 | -53.15 Mn |
| Mar 31, 2024 | -2.32 Mn |
| Mar 31, 2024 | -2.32 Mn |
| Dec 31, 2023 | 22.32 Mn |
| Dec 31, 2023 | 22.32 Mn |